These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 20528225

  • 1. Salirasib in the treatment of pancreatic cancer.
    Bustinza-Linares E, Kurzrock R, Tsimberidou AM.
    Future Oncol; 2010 Jun; 6(6):885-91. PubMed ID: 20528225
    [Abstract] [Full Text] [Related]

  • 2. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M.
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [Abstract] [Full Text] [Related]

  • 3. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y.
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
    [Abstract] [Full Text] [Related]

  • 4. An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.
    Furuse J, Kurata T, Okano N, Fujisaka Y, Naruge D, Shimizu T, Kitamura H, Iwasa T, Nagashima F, Nakagawa K.
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):511-519. PubMed ID: 29992354
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
    Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.
    Mol Cancer; 2010 Sep 22; 9():256. PubMed ID: 20860815
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
    Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y.
    Clin Cancer Res; 2002 Feb 22; 8(2):555-65. PubMed ID: 11839677
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B, Ehrlich M, Haklai R, Kloog Y.
    Methods Enzymol; 2008 Feb 22; 439():467-89. PubMed ID: 18374183
    [Abstract] [Full Text] [Related]

  • 12. FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.
    Goldberg L, Israeli R, Kloog Y.
    Cell Death Dis; 2012 Mar 15; 3(3):e284. PubMed ID: 22419113
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
    Du R, Sullivan DK, Azizian NG, Liu Y, Li Y.
    BMC Cancer; 2021 Mar 06; 21(1):237. PubMed ID: 33676427
    [Abstract] [Full Text] [Related]

  • 14. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
    Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y.
    Mol Cancer Ther; 2010 Aug 06; 9(8):2208-19. PubMed ID: 20682656
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ras chaperones: new targets for cancer and immunotherapy.
    Kloog Y, Elad-Sfadia G, Haklai R, Mor A.
    Enzymes; 2013 Aug 06; 33 Pt A():267-89. PubMed ID: 25033809
    [Abstract] [Full Text] [Related]

  • 17. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
    Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, Gierschik P, Kloog Y.
    Oncogene; 1999 Apr 22; 18(16):2579-88. PubMed ID: 10353601
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
    Egozi Y, Weisz B, Gana-Weisz M, Ben-Baruch G, Kloog Y.
    Int J Cancer; 1999 Mar 15; 80(6):911-8. PubMed ID: 10074926
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.